Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 17/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 14/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25848934 | 0.90 | PPARA (0.48) | EPHX2HDAC3HDAC8HDAC6 | |
| SCHEMBL25848828 | 0.86 | EPHX2 (0.53) | EPHX2NR1H4CA1CA2HDAC3 | |
| SCHEMBL25848823 | 0.85 | EPHX2 (0.61) | EPHX2NR1H4CA1CA2HDAC3 | |
| SCHEMBL25848943 | 0.81 | HDAC3 (0.49) | EPHX2NR1H4HDAC3HDAC6RAB9A | |
| SCHEMBL25848935 | 0.80 | HDAC3 (0.43) | EPHX2NR1H4CA1CA2HDAC3 | |
| SCHEMBL25848863 | 0.80 | HDAC1 (0.47) | EPHX2NR1H4CA1CA2HDAC3 | |
| SCHEMBL24196677 | 0.79 | LSS (0.49) | EPHX2HDAC3HDAC8HDAC6 | |
| SCHEMBL24196168 | 0.78 | EPHX2 (0.56) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL25848867 | 0.76 | HDAC3 (0.49) | EPHX2NR1H4CA1CA2HDAC3 | |
| SCHEMBL25849324 | 0.75 | PPARA (0.49) | EPHX2HDAC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | EPHX2 2590/4885NR1H4 3085/4885CA1 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.